Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650577 | 1.00 | RXRA (1.00) | RXRA | |
| SCHEMBL5650580 | 1.00 | RXRA (1.00) | RXRA | |
| Tromethamine SCHEMBL5792868 | 0.95 | RXRA (0.90) | RXRA | |
| SCHEMBL5789587 | 0.94 | RXRA (0.89) | RXRA | |
| SCHEMBL5789586 | 0.94 | RXRA (0.89) | RXRA | |
| SCHEMBL5791284 | 0.89 | RXRA (0.81) | RXRA | |
| SCHEMBL5791282 | 0.89 | RXRA (0.81) | RXRA | |
| SCHEMBL5790104 | 0.89 | RXRA (0.79) | RXRA | |
| SCHEMBL5790100 | 0.89 | RXRA (0.79) | RXRA | |
| SCHEMBL5865606 | 0.88 | RXRA (0.79) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7723326-B2 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723326-B2 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| WO-2007041112-A2 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041076-A2 | 1,2,3,5-TETRAHYDRO-CYCLOPENTAL[C]QUINOLIN-4-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041077-A2 | HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. | 2007-04-05 | — | — | US | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078160-A1 | DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES | NR1H2, RXRA, NR1H3 | RXRA 2/4885 |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | RXRA 2926/4885 |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | RXRA 3327/4885 |
| US-20070078129-A1 | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | NR1H2, NR1H3, RXRA | RXRA 3/4885 |
| US-20070099937-A1 | Substituted Pyrrolones As Allosteric Modulators of Glucokinase | GCK, GCKR, PDXK | RXRA 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.